Statins for people at low risk: Independent review of the trial data is an essential next step

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Parish, Emma ^a   Bloom, Theodora ^a   Godlee, Fiona ^a  

^a British Medical Journal Technology Assessment Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACCESS TO INFORMATION; DATA ANALYSIS; DRUG INFORMATION; DRUG SAFETY; EDITORIAL; HUMAN; LOW RISK POPULATION; MORTALITY; PRIORITY JOURNAL; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); HEART DISEASES; RISK; STROKE;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; HEART DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK; STROKE;

EID: 84940421525     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h3908     Document Type: Editorial

References (15)

1. British Heart Foundation. Statins. www.bhf.org.uk/heart-health/treatments/statins.
2. National Institute for Health and Care Excellence. NICE clinical guideline 181. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2015. www.nice.org.uk/guidance/cg181/chapter/1-recommendations#lipid-modification-Therapy-for-The-primaryand-secondary-prevention-of-cvd-2.
3. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1-45.
4. Boseley S. Doctors' fears over statins may cost lives, says top medical researcher. Guardian 2015 Mar 21. www.theguardian.com/society/2014/mar/21/-sp-doctors-fearsover-statins-may-cost-lives-says-Top-medical-researcher.
5. Ferket B, van Kempen BJH, Heeringa J, et al. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: A modelling study. PLoS Med 2012;9:e1001361.
6. Price C. Giving patients statins "buys them just fourteen days of life." Pulse 2013 May 1. www.pulsetoday.co.uk/clinical/cardiovascular/giving-patients-statins-buys-Them-justfourteen-days-of-life/20002819.article#.Vag27nnbLIU.
7. Heath I, Evans S, Furberg C, et al. Report of the independent panel considering the retraction of two articles in The BMJ. BMJ 2014;349:g5176.
8. Johnston L. Statins expert calls for safety checks over the drug. Sunday Expres s 2015 Feb 15. www.express.co.uk/news/uk/558249/statins-expert-heart-drug-rory-collins.
9. Hawkes N. Results of investigation into statin side effects due by end of year. BMJ 2015;350:h957.
10. Krumholz H. Why data sharing should be the expected norm. BMJ 2015;350:h599.
11. Wise J. England's chief medical officer asks for review of drug evaluation in wake of statins controversy. BMJ 2015;350:h3300.
12. Goldacre B. How medicine is broken, and how we can fix it. BMJ 2015;350:h3397.
13. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ 2013;347:f6123
14. Malhotra A. Saturated fat is not the major issue. BMJ 2013;347:f6340.
15. Godlee F. Statins and The BMJ. BMJ 2014;349:g5038.